Studies have shown that the active form of human B lymphocyte kinase (BLK) is a proto-oncogene and targeting it using an inhibitor has shown anti-proliferative effect in cutaneous T-cell lymphoma (CTCL) [66]. The gene discussed is BLK; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.